Targeting ATR in cancer.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Early cancer chemotherapy utilized DNA damaging agents like mustard gas, leading to genotoxic drug development.
• The efficacy of genotoxic therapies is often limited by severe side effects on healthy cells.
• Exploiting cancer-specific DNA damage presents a refined therapeutic approach.

Purpose of the Study:

• To review the biological rationale for targeting the ataxia telangiectasia and Rad3-related protein (ATR) kinase in cancer therapy.
• To discuss the potential of ATR inhibitors as a promising alternative cancer treatment.
• To explore predictive biomarkers for patient selection in ATR inhibitor therapy.

Main Methods:

• Literature review of DNA damaging agents and cancer treatment strategies.
• Analysis of the role of replication stress (RS) in cancer genomic instability.
• Discussion of the biological mechanisms and clinical relevance of ATR inhibitors.

Main Results:

• Replication stress (RS) is a significant driver of genomic instability in cancer.
• Targeting the ATR kinase, a key regulator of the RS response, is a promising therapeutic strategy.
• ATR inhibitors are advancing into clinical trials, indicating therapeutic potential.

Conclusions:

• Targeting ATR represents a refined approach to cancer therapy, focusing on cancer cell-specific vulnerabilities.
• Further research into biomarkers is crucial for optimizing patient selection and treatment efficacy for ATR inhibitors.
• ATR inhibition holds promise for improving cancer treatment outcomes by exploiting replication stress pathways.